Rethinking Neurodegenerative Disease Treatment: Target Multiple Pathological Proteins, Not Just One
Nearly all major neurodegenerative diseases – from Alzheimer’s to Parkinson’s – are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta (Aβ), alpha-synuclein (α-syn), or TDP-43. As such, investigational drugs and studies aimed at preventing or slowing the disease often hone in on just one of these respective proteins. However, targeting multiple proteins—known as “proteinopathies”—at once may be the real key, according to a recent study published in Brain by Penn Medicine researchers.
IOA IN THE NEWS
07/06/18Proteinopathies, the misfolded proteins responsible for neuron deaths, have a claim to fame when it comes to rare neurodegenerative…
03/06/18The epigenomic landscape of Alzheimer’s disease brains is profiled in a new study from from the Perelman School of Medicine.
02/26/18Some immune cells in the brain can protect it from the damaging effects of faulty TDP-43 protein, preventing the progression…
Join the nearly 200 Institute on Aging Fellows and Associate Fellows and experience robust collaborative opportunities in aging at Penn, for funding opportunity alerts, pilot research grant opportunities, and updates on IOA activities.
FEATURED VIDEOVideo Archive
Penn Medicine's 5K for the IOA and the Memory Mile Walk
Save the date:
Sunday, September 23, 2018
8:00am @ Penn Park
MAKE A GIFT
Support aging-related research, education, and care at the IOA!
THE SCIENCE OF AGING NEWSLETTER
In this issue:
- The 11th Annual Vincent J. Cristofalo Lectureship
- Brain Immune System is Key to Recovery from Motor Neuron Disease
- FY 2019 Pilot Award Announcement
… and more!
Download the 2018 Spring Newsletter here
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.